Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-t6hkb Total loading time: 0 Render date: 2024-07-13T15:43:00.616Z Has data issue: false hasContentIssue false

14 - Management of at-risk exposures and infection control in custody

Published online by Cambridge University Press:  12 August 2009

W. D. S. McLay
Affiliation:
University of Glasgow
Get access

Summary

Introduction

This chapter provides information on the prevalence of hepatitis B, hepatitis C and human immunodeficiency virus (HIV) – collectively referred to as blood-borne viruses (BBVs) – in risk groups, identifies the risks of specific body fluids and the routes of transmission. It further acts as a guide to the immediate management of at-risk exposures from BBVs both for the recipient and the contact, and any follow-up management this may entail. It will also cover some basic infection control guidance that will be helpful in the safe and practical day-to-day running of a custody suite. Although not exhaustive, it aims to cover the more commonly raised concerns and how best they should be managed.

Prevalence of BBVs: at-risk groups, body fluids and routes of transmission

Hepatitis B

Around 350 million people worldwide are chronically infected with hepatitis B and are therefore at risk of developing chronic liver disease. There are around 180000 people in this category in the UK. In general the world can be divided into three broad areas by prevalence of chronic infection (Table 14.1). About 75% of the world's population live in areas of high prevalence.

The virus can be transmitted through contact with body fluids (blood, saliva, semen, vaginal fluids, sweat, breast milk and any other if bloodstained) via percutaneous or mucosal exposure. In areas of high prevalence, infection most commonly occurs perinatally or in early childhood. In areas of intermediate prevalence, needle sharing, acupuncture, tattooing and body piercing are also important modes of transmission.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

,PHLS Hepatitis Subcommittee (2005) Shooting Up. Infections Among Injecting Drug Users in the United Kingdom 2005.
,Health Protection Agency (2004) Focus on Prevention. HIV and other sexually transmitted infections in the United Kingdom in 2003. An update November 2004. Available at www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_c/1203496898041?p=1158945066450
Fisher, M, Benn, P, Evans, B, et al. (2006) UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. International Journal of STD & AIDS 17: 81–92.CrossRefGoogle ScholarPubMed
,Department of Health (2006) Hepatitis B. In: Immunization Against Infectious Diseases pp. 161–84. Available at www.dh.gov.uk/en/Publicheath/Healthprotection/Immunisation/Greenbook/DH_4097254
,Department of Health (2000) HIV Post-exposure Prophylaxis. Guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS.
,Department of Health (2004) HIV Post-exposure Prophylaxis. Guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS, 2nd edn. Available at www.advisorybodies.doh.gov.uk/eaga/publications.htm
,Department of Health (1996) Guidelines for Pre-test Discussion on HIV Testing. [PL/CMO/(96)1]. Available at www.advisorybodies.doh.gov.uk/eaga/guidelineshivtestdiscuss.pdf
,NICE (2004) Technology Appraisals; Hepatitis C – pegylated interferons, ribavirin and alfa interferon (TA75). Available at www.nice.org.uk/Guidance/TA75
,NICE (2006) Technology Appraisals, Hepatitis C – pegylated interferon alfa and ribavirin for treatment of mild chronic hepatitis C (TA106). Available at www.nice.org.uk/nicemedia/pdf/TA106 publicinfo.pdf
,Department of Health (2006) Environment and Sustainability – Health Technical Memorandum 07–01: Safe Management of Healthcare Waste. 2006. Available at www.dh.gov.uk/en/Publications and statistics/Publications/Publications Policy And Guidance/DH_063274
,Health Protection Agency (2007) Interim Guidance on Diagnosis and Management of PVL-Associated Staphylococcal Infections in the UK (last modified 13 March 2007). Available at www.dh.gov.uk/en/Aboutus/Ministers and DepartmentLeaders/ChiefMedicalOfficer/Feature
,Health Protection Agency (2006) An Update – October 2006. Available at www.hpa.org.uk/infection/topics_a-z/injectingdrugusers
http://www.advisorybodies.doh.gov.uk/jcvi/

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×